AI names and growth stocks have stumbled in early 2025. 2024’s big stock market winners are among the worst performers in recent weeks. AI stocks have plunged double digits amid a wave of challenging ...

With proper data governance, the pharma industry can improve patient-centricity in trials and bring lifesaving therapies to ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Bristol Myers Squibb is axing another 280 jobs as part of its $1.5 billion cost-cutting plan. The company is laying off 223 ...

KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including engineered tumor-infiltrating lymphocyte (eTIL ®) programs, today announced ...

Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. Garay Alonso as Chief Financial ...

Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

A Peninsula company that makes medical devices for body sculpting, tattoo removal, acne and more hopes to go private and ...

JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

The global orphan drug market size was USD 154.20 Billion in 2022 and is expected to register a rapid revenue CAGR of 12.3 % ...